ACS Medicinal Chemistry Letters
ACS Medicinal Chemistry Letters
5 years ago

Structure–Activity Relationship Studies with Tetrahydroquinoline Analogs as EPAC Inhibitors

Structure–Activity Relationship Studies with Tetrahydroquinoline Analogs as EPAC Inhibitors
Jered C. Garrison, Yogesh A. Sonawane, Amarnath Natarajan, Yingmin Zhu, Edward L. Ezell, Xiaodong Cheng, Muhammad Zahid
EPAC proteins are therapeutic targets for the potential treatment of cardiac hypertrophy and cancer metastasis. Several laboratories use a tetrahydroquinoline analog, CE3F4, to dissect the role of EPAC1 in various disease states. Here, we report SAR studies with tetrahydroquinoline analogs that explore various functional groups. The most potent EPAC inhibitor 12a exists as a mixture of inseparable E (major) and Z (minor) rotamers. The rotation about the N-formyl group indeed impacts the activity against EPAC.

Publisher URL: http://dx.doi.org/10.1021/acsmedchemlett.7b00358

DOI: 10.1021/acsmedchemlett.7b00358

You might also like
Discover & Discuss Important Research

Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.